Unknown

Dataset Information

0

Hyaluronic Acid-Guided Cerasome Nano-Agents for Simultaneous Imaging and Treatment of Advanced Atherosclerosis.


ABSTRACT: Early noninvasive screening and regression therapy for vulnerable atherosclerotic plaques remain challenging. In this study, it is aimed to develop a new approach for the active targeting of atherosclerotic plaques with nano-agents to aid imaging and treatment. Biocompatible hyaluronic acid (HA)-guided cerasomes are generated to selectively target CD44-positive cells within the plaque in in vitro studies and in vivo testing in Apoe-/- mice. Rosuvastatin (RST) is encapsulated in the HA-guided cerasome nano-formulation to produce HA-CC-RST, which results in significant plaque regression as compared to treatment with the free drug. Moreover, gadodiamide-loaded HA-CC enhances magnetic resonance images of vulnerable plaques, thereby attaining the goal of improved simultaneous treatment and imaging. Transcriptomic analysis confirms plaque regression with HA-CC-RST treatment, which potentially benefits from the anti-inflammatory effect of RST. In summary, a safe and efficient nano-formulation for the targeted delivery of active agents to atherosclerotic plaques is developed and may be applicable to other diagnostic and therapeutic agents for atherosclerosis treatment.

SUBMITTER: Ma Q 

PROVIDER: S-EPMC9929131 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Hyaluronic Acid-Guided Cerasome Nano-Agents for Simultaneous Imaging and Treatment of Advanced Atherosclerosis.

Ma Qian Q   Wu Sijing S   Yang Ling L   Wei Yaohua Y   He Chaoyong C   Wang Wenshan W   Zhao Yingxin Y   Wang Zhijian Z   Yang Shiwei S   Shi Dongmei D   Liu Yuyang Y   Zhou Zhiming Z   Sun Jiefang J   Zhou Yujie Y  

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20221218 5


Early noninvasive screening and regression therapy for vulnerable atherosclerotic plaques remain challenging. In this study, it is aimed to develop a new approach for the active targeting of atherosclerotic plaques with nano-agents to aid imaging and treatment. Biocompatible hyaluronic acid (HA)-guided cerasomes are generated to selectively target CD44-positive cells within the plaque in in vitro studies and in vivo testing in Apoe<sup>-/-</sup> mice. Rosuvastatin (RST) is encapsulated in the HA  ...[more]

Similar Datasets

| S-EPMC4930365 | biostudies-literature
| S-EPMC9449492 | biostudies-literature
| S-EPMC10995877 | biostudies-literature
| S-EPMC7183523 | biostudies-literature
| S-EPMC5573055 | biostudies-literature
| S-EPMC9563174 | biostudies-literature
| S-EPMC9801563 | biostudies-literature
| S-EPMC3546735 | biostudies-literature
| S-EPMC9181619 | biostudies-literature
| S-EPMC8163372 | biostudies-literature